Progressive Care (OTCQB: RXMD) is an organization based in Florida that, through its wholly owned subsidiaries PharmcoRx Pharmacy and ClearMetrX, offers personalized care services and technology to support the managed health care industries. “Progressive Care offers a wide range of innovative solutions to address the dispensing, delivery, dosing and reimbursement of clinically intensive, high-cost drugs. Progressive Care currently operates four pharmacies in Florida, which generate the majority of its revenue,” reads a recent article. “Pharmacy revenue is derived from dispensing medications, third-party administrative services to 340B-covered entities, and medication therapy management (‘MTM’) services. The company also provides customized management, patient health risk reviews and free same- and next-day delivery. Its focus is on complex diseases that require multiyear or lifelong therapy, driving recurring revenue and sustainable growth. Progressive Care’s pharmacy revenue growth stems from its expanding breadth of services, new drugs coming to market, new indications for existing drugs, volume growth with current clients, and addition of new customers resulting from its emphasis on higher patient engagement, free delivery to the patient, and clinical expertise. With licenses in 14 states, Progressive Care is poised for national expansion.”
To view the full article, visit https://ibn.fm/o4oqT
About Progressive Care:
Progressive Care, through its subsidiaries, is a Florida health services organization. The company provides third-party administration (“TPA”), data management, COVID-19 related diagnostics and vaccinations, 340B contracted pharmacy services, prescription pharmaceuticals, compounded medications, tele-pharmacy services, the sale of anti-retroviral medications, medication therapy management (“MTM”), the supply of prescription medications to long-term care facilities, and health practice risk management. For more information about Progressive Care, visit www.ProgressiveCareUS.com.
NOTE TO INVESTORS: The latest news and updates relating to RXMD are available in the company’s newsroom at https://ibn.fm/RXMD
About BioMedWire
BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)
For more information please visit https://www.biomedwire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork.
Regentis Biomaterials (NYSE American: RGNT), a regenerative medicine company focused on tissue repair solutions, announced…
Quantum BioPharma (NASDAQ: QNTM) announced that it has filed a supplement to its Sept. 28,…
Earth Science Tech (OTCQB: ETST), a diversified holding company operating across healthcare, pharmacy, technology, telemedicine,…
Disseminated on behalf of Adaptogenics Health Corp. and may include paid advertising. Adaptogenics (CSE: ADPT)…
VERAXA Biotech (NASDAQ: VRXA) is expanding its use of human-relevant preclinical testing methods across its…
Quantum BioPharma (NASDAQ: QNTM) has signed a Study Start-Up Agreement with Thermo Fisher Scientific’s clinical…